Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy
- PMID: 28463792
- DOI: 10.1016/j.biopha.2017.02.112
Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy
Abstract
Purpose: Chemotherapy is the current standard treatment for Non-Hodgkin's lymphoma (NHL). Combination therapy is emerging as an important strategy for a better long-term prognosis with decreased side effects, maximized therapeutic effect. The aim of this study is to deliver vincristine (VCR) and quercetin (QU) with synergistic drug ratios through lipid-polymeric nanocarriers (LPNs) for the lymphoma combination chemotherapy METHODS: In this present study, we constructed VCR and QU dual-loaded LPNs (VCR/QU LPNs) and investigated their antitumor efficacy in vitro cell culture models and a tumor xenograft mouse model.
Results: The formulated VCR/QU LPNs exhibited nano-size, negative zeta potential with sustained release profile in vitro. The dual drug loaded LPNs exhibited the best antitumor efficacy in vitro and in vivo.
Conclusion: It could be concluded that VCR/QU LPNs can combine the efficiency of these two drugs, bring about synergistic effect. Co-encapsulation of VCR and QN in the same LPNs has potential as a novel therapeutic approach to overcome chemo-resistant lymphoma.
Keywords: Drug resistance; Lymphoma; Non-Hodgkin lymphoma; Quercetin; Vincristine.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical